上海交通大学学报（医学版）

上海交通大学学报（医学版） ›› 2019, Vol. 39 ›› Issue (12): 1456-.doi: 10.3969/j.issn.1674-8115.2019.12.019

• 综述 • 上一篇    下一篇

吡格列酮抗抑郁作用研究进展

史一凡1，黄 佳1，方贻儒1, 2, 3   

  1. 1.上海交通大学医学院附属精神卫生中心心境障碍科，上海200030；2.中国科学院脑科学与智能技术卓越创新中心，上海200030；3.上海市重性精神病重点实验室，上海200030
  • 出版日期:2019-12-28 发布日期:2020-02-06
  • 通讯作者: 方贻儒，电子信箱：yirufang@aliyun.com。
  • 作者简介:史一凡（1995—），女，博士生；电子信箱：artemis_syf@163.com。
  • 基金资助:
    国家十三五重大专项（2016YFC1307100）；国家自然科学基金面上项目（81771465）

Progress in antidepressant effects of pioglitazone

SHI Yi-fan, HUANG Jia, FANG Yi-ru   

  1. 1. Division of Mood Disorder, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; 2. CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai 200030, China; 3. Shanghai Key Laboratory of Psychotic Disorders, Shanghai 200030, China
  • Online:2019-12-28 Published:2020-02-06
  • Supported by:
    National Key R&D Program of China, 2016YFC1307100; National Natural Science Foundation of China, 81771465

PDF (PC)

492

摘要： 吡格列酮作为一种过氧化物酶体增殖激活受体γ（peroxisome proliferator-activated receptor γ，PPARγ）的激动剂，可能参与糖脂代谢、氧化应激、免疫炎症反应的调节，从而起到改善抑郁的作用。研究发现，吡格列酮对抑郁症尤其是治疗抵抗和共病代谢综合征的患者疗效较好，有望成为抑郁症治疗的新方案。该文综述吡格列酮在抑郁症临床应用及相关机制的研究进展，以期为后续研究提供理论依据和支持。

关键词: 吡格列酮, 抑郁症, 过氧化物酶体增殖激活受体&, gamma

Abstract:

As an agonist of peroxisome proliferator-activated receptor γ (PPARγ), pioglitazone may be involved in the regulation of glycolipid metabolism, oxidative stress and immune inflammatory response, thereby improving depression. Studies find that pioglitazone is effective in treating depression, especially in patients with resistance and comorbid metabolic syndrome, and is expected to be a new treatment for depression. This article reviews the research progress of pioglitazone in clinical application and related mechanisms of depression, into provide theoretical basis and support for subsequent research.

Key words: pioglitazone, depressive disorder, peroxisome proliferator-activated receptor γ